ArticleEFSA journal. European Food Safety Authority2026
Possible alignment of the EU BSE surveillance with the new WOAH provisions.
Article in EFSA journal. European Food Safety Authority, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Possible alignment of the EU BSE surveillance with the new WOAH provisions.EFSA journal. European Food Safety Authority · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The European Commission requested the assessment of the capacity of the surveillance provisions of the World Organization for Animal Health (WOAH) to detect bovine spongiform encephalopathy (BSE) cases (C-, H- and L-type) in the European Union (EU) and to propose if any current EU surveillance provisions should be kept. The WOAH provisions stipulate that BSE surveillance should target animals on the BSE clinical spectrum and require the implementation of standardised clinical protocols for selecting animals for testing. Based on expert judgement of retrospective clinical data, between 5% and 49% of the 55 BSE cases detected in the EU & UK since 2015 would have been selected for testing by the WOAH surveillance. Assuming the current EU surveillance, a back-calculation model predicted a very low number of BSE cases detected for the period 2025-2029: 0.0196 for C-BSE, 10.94 for H-BSE and 9.13 for L-BSE. As no classical BSE (C-BSE) cases are expected, the application of the WOAH provisions would primarily impact the detection of atypical BSE (H-BSE and L-BSE), with an estimated detection over the next 5 years of between zero and five H-BSE cases and between zero and four L-BSE cases. Supplementing the WOAH provisions with systematic testing of fallen stock (with or without emergency slaughter) with increased age threshold of 60 or 72 months would achieve a detection capability close to current EU levels. This approach would enable the documentation of the effectiveness of BSE control measures, provide scientific assurance that the decline in C-BSE is sustained and allow atypical BSE trends to be monitored reliably while maintaining the sensitivity required to detect any re-emergence of C-BSE. Finally, this would contribute to risk mitigation by triggering immediate statutory control measures when cases are detected. Modifications of EU surveillance requirements should consider any potential adjustments to other available BSE control measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.